Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Miravo Healthcare
BioNTech Looks For Faster Entry Into Cancer Therapies As COVID-19 Recedes
BioNTech continues to earn big money from its COVID-19 vaccine, but wants to become an on-market cancer company sooner rather than later.
Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
Finance Watch: VC Round Extensions Attractive While Stock Market Wobbles
Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.
Dr Reddy’s Debuts US Vimovo Rival At Risk
Dr Reddy’s has announced the launch of the first US generic version of Vimovo delayed-release tablets. However, Nuvo has warned that the at-risk launch infringes patents protecting the arthritis pain treatment until May 2022.
- Medical Devices
- Drug Delivery
- OTC, Consumer
- Specialty Pharmaceuticals
- Controlled Release
- Topical Delivery
- Other Names / Subsidiaries
- Dimethaid Research
- Nuvo Ireland
- Nuvo Research, Inc.
- Nuvo Pharmaceuticals, Inc.
- Oxo Chemie GmbH
- Tribute Pharmaceuticals Canada Inc.
- ZARS Pharma, Inc.,
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.